Cargando…
Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea
BACKGROUND AND AIMS: This study aims to investigate the cost-effectiveness of a one-time hepatitis C virus (HCV) screening and treatment program in South Korea where hepatitis B virus (HBV) prevails, in people aged 40–70, compared to current practice (no screening). METHODS: A published Markov model...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5218507/ https://www.ncbi.nlm.nih.gov/pubmed/28060834 http://dx.doi.org/10.1371/journal.pone.0167770 |
_version_ | 1782492295193427968 |
---|---|
author | Kim, Do Young Han, Kwang-Hyub Jun, Byungyool Kim, Tae Hyun Park, Sohee Ward, Thomas Webster, Samantha McEwan, Phil |
author_facet | Kim, Do Young Han, Kwang-Hyub Jun, Byungyool Kim, Tae Hyun Park, Sohee Ward, Thomas Webster, Samantha McEwan, Phil |
author_sort | Kim, Do Young |
collection | PubMed |
description | BACKGROUND AND AIMS: This study aims to investigate the cost-effectiveness of a one-time hepatitis C virus (HCV) screening and treatment program in South Korea where hepatitis B virus (HBV) prevails, in people aged 40–70, compared to current practice (no screening). METHODS: A published Markov model was used in conjunction with a screening and treatment decision tree to model patient cohorts, aged 40–49, 50–59 and 60–69 years, distributed across chronic hepatitis C (CHC) and compensated cirrhosis (CC) health states (82.5% and 17.5%, respectively). Based on a published seroepidemiology study, HCV prevalence was estimated at 0.60%, 0.80% and 1.53%, respectively. An estimated 71.7% of the population was screened. Post-diagnosis, 39.4% of patients were treated with a newly available all-oral direct-acting antiviral (DAA) regimen over 5 years. Published rates of sustained virologic response, disease management costs, transition rates and utilities were utilised. RESULTS: Screening resulted in the identification of 43,635 previously undiagnosed patients across all cohorts. One-time HCV screening and treatment was estimated to be cost-effective across all cohorts; predicted incremental cost-effectiveness ratios ranged from $5,714 to $8,889 per quality-adjusted life year gained. Incremental costs associated with screening, treatment and disease management ranged from $156.47 to $181.85 million USD; lifetime costs-offsets associated with the avoidance of end stage liver disease complications ranged from $51.47 to $57.48 million USD. CONCLUSIONS: One-time HCV screening and treatment in South Korean people aged 40–70 is likely to be highly cost-effective compared to the current practice of no screening. |
format | Online Article Text |
id | pubmed-5218507 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-52185072017-01-19 Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea Kim, Do Young Han, Kwang-Hyub Jun, Byungyool Kim, Tae Hyun Park, Sohee Ward, Thomas Webster, Samantha McEwan, Phil PLoS One Research Article BACKGROUND AND AIMS: This study aims to investigate the cost-effectiveness of a one-time hepatitis C virus (HCV) screening and treatment program in South Korea where hepatitis B virus (HBV) prevails, in people aged 40–70, compared to current practice (no screening). METHODS: A published Markov model was used in conjunction with a screening and treatment decision tree to model patient cohorts, aged 40–49, 50–59 and 60–69 years, distributed across chronic hepatitis C (CHC) and compensated cirrhosis (CC) health states (82.5% and 17.5%, respectively). Based on a published seroepidemiology study, HCV prevalence was estimated at 0.60%, 0.80% and 1.53%, respectively. An estimated 71.7% of the population was screened. Post-diagnosis, 39.4% of patients were treated with a newly available all-oral direct-acting antiviral (DAA) regimen over 5 years. Published rates of sustained virologic response, disease management costs, transition rates and utilities were utilised. RESULTS: Screening resulted in the identification of 43,635 previously undiagnosed patients across all cohorts. One-time HCV screening and treatment was estimated to be cost-effective across all cohorts; predicted incremental cost-effectiveness ratios ranged from $5,714 to $8,889 per quality-adjusted life year gained. Incremental costs associated with screening, treatment and disease management ranged from $156.47 to $181.85 million USD; lifetime costs-offsets associated with the avoidance of end stage liver disease complications ranged from $51.47 to $57.48 million USD. CONCLUSIONS: One-time HCV screening and treatment in South Korean people aged 40–70 is likely to be highly cost-effective compared to the current practice of no screening. Public Library of Science 2017-01-06 /pmc/articles/PMC5218507/ /pubmed/28060834 http://dx.doi.org/10.1371/journal.pone.0167770 Text en © 2017 Kim et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Kim, Do Young Han, Kwang-Hyub Jun, Byungyool Kim, Tae Hyun Park, Sohee Ward, Thomas Webster, Samantha McEwan, Phil Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea |
title | Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea |
title_full | Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea |
title_fullStr | Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea |
title_full_unstemmed | Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea |
title_short | Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea |
title_sort | estimating the cost-effectiveness of one-time screening and treatment for hepatitis c in korea |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5218507/ https://www.ncbi.nlm.nih.gov/pubmed/28060834 http://dx.doi.org/10.1371/journal.pone.0167770 |
work_keys_str_mv | AT kimdoyoung estimatingthecosteffectivenessofonetimescreeningandtreatmentforhepatitiscinkorea AT hankwanghyub estimatingthecosteffectivenessofonetimescreeningandtreatmentforhepatitiscinkorea AT junbyungyool estimatingthecosteffectivenessofonetimescreeningandtreatmentforhepatitiscinkorea AT kimtaehyun estimatingthecosteffectivenessofonetimescreeningandtreatmentforhepatitiscinkorea AT parksohee estimatingthecosteffectivenessofonetimescreeningandtreatmentforhepatitiscinkorea AT wardthomas estimatingthecosteffectivenessofonetimescreeningandtreatmentforhepatitiscinkorea AT webstersamantha estimatingthecosteffectivenessofonetimescreeningandtreatmentforhepatitiscinkorea AT mcewanphil estimatingthecosteffectivenessofonetimescreeningandtreatmentforhepatitiscinkorea |